novo nordisk patent semaglutide China's weight-loss drug makers take on global giants as expires Patent Expiry Day: Novo Nordisk

doi: 10.1038/s41586-025-08723-7

At present, even though the comparative efficacy of tirzepatide vs these higher dosing regimens of dulaglutide and semaglutide is unknown, available data suggest that tirzepatide could be a reasonable treatment option when glycaemic control and body weight loss are therapeutic priorities

The anti-inflammatory properties of GLP-1 receptor agonists could play a protective role, though researchers are still investigating the precise mechanisms

So I have seen these all over Tik Tok and decided to give them a try since I have been stagnant for about 3 weeks now

Foods That Fight Constipation Fiber Is Your Friend Constipation happens to many people taking tirzepatide

2023 Zepbound (tirzepatide) The first dual GIP/GLP-1 receptor agonist approved for obesity, delivering weight-loss results approaching those seen with metabolic surgery in many patients